BACKGROUND: Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. A considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule. METHODS: In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG <10 AU/ml) to the previous 2-dose vaccination schedule. The primary outcome was the difference in the rate of a positive antibody response (SARS-CoV-2 IgG ≥10 AU/ml) between one and two booster doses at 1 month after the final booster dose. RESULTS: A positive humoral response was observed in 36 (62%) patients receiving two booster doses and in 28 (44%) patients receiving one booster dose (odds ratio [OR], 2.10, 95% confidence interval [CI], 1.02-4.34, p = .043). Moreover, median SARS-CoV-2 IgG levels were higher with two booster doses (p = .009). The number of patients with positive virus neutralizing antibody (VNA) levels was numerically higher with two booster doses compared to one booster dose, but without statistical significance (66% vs. 50%, p = .084). There was no significant difference in positive seroconversions rate and antibody levels between mRNA-1273 and BNT162b2. CONCLUSION: A higher number of kidney transplant recipients achieved a positive antibody response after two booster doses compared to one booster dose.

Biomedical Centre Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Immunochemistry Diagnostics Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Czech Republic

Department of Immunology and Allergology Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Czech Republic

Department of Internal Medicine 1 Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Czech Republic

Department of Pharmacology and Toxicology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Reischig T, Kacer M, Vlas T, et al. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. Am J Transplant. 2022;22(3):801-812.

Rozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021;27(8):1173.e1-1173.e4.

Rincon-Arevalo H, Choi M, Stefanski AL, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021;6(60):eabj1031.

Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719-2726.

Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21(8):2727-2739.

Dolff S, Zhou B, Korth J, et al. Evidence of cell-mediated immune response in kidney transplants with a negative mRNA vaccine antibody response. Kidney Int. 2021;100(2):479-480.

Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131(14):e150175.

Kemlin D, Gemander N, Depickère S, et al. Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients. Am J Transplant. 2023:S1600-6135(23):00300-00303.

Kamar N, Abravanel F, Marion O. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661-662.

Werbel WA, Boyarsky BJ, Ou MT. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174:1330-1332.

Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063-1065.

Kumar D, Ferreira VH, Hall VG, et al. Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine: secondary analysis of a randomized trial. Ann Intern Med. 2022;175(2):226-233.

Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):165-171.

Kho MML, Messchendorp AL, Frölke SC, et al. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. Lancet Infect Dis. 2022:S1473-3099(22):00650-00658.

Bruminhent J, Setthaudom C, Phornkittikorn P, et al. An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: a randomized controlled trial (CVIM 4 study). Am J Transplant. 2022;22(11):2651-2660.

Mitchell J, Alejo JL, Chiang TPY, et al. Antibody response to a fourth dose of SARS-CoV-2 vaccine in solid organ transplant recipients: an update. Transplantation. 2022;106(7):e338-e340.

Kamar N, Abravanel F, Marion O, et al. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant. JAMA Netw Open. 2021;4(11):e2136030.

Midtvedt K, Vaage JT, Heldal K, et al. Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response. Am J Transplant. 2022; 22(11):2704-2706. doi:10.1111/ajt.17091

Cristelli MP, Nakamura MR, Viana LA, et al. The fourth dose of CoronaVac vaccine results in a small increase of seroconversion and antibody values among kidney transplant recipients. Transplantation. 2022;106(9):e420-e421.

FDA. Access SARS-CoV-2 IgG II (C69057), instructions for use, 2021. Accessed February 08, 2023. https://www.fda.gov/media/146901/download

Valcourt EJ, Manguiat K, Robinson A, et al. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). Diagn Microbiol Infect Dis. 2021;99:115294.

Mombelli M, Rettby N, Perreau M, et al. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: a randomized controlled trial. Vaccine. 2018;36(41):6163-6169.

Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450.

Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920-1931.

Vargas JI, Jensen D, Martínez F, et al. Comparative efficacy of a high-dose vs standard-dose hepatitis B revaccination schedule among patients with HIV: a randomized clinical trial. JAMA Netw Open. 2021;4(8):e2120929.

Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427-2438.

Bruminhent J, Setthaudom C, Kitpermkiat R, et al. Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients. Sci Rep. 2022;12(1):3587.

Šimánek V, Pecen L, Krátká Z, et al. Five commercial immunoassays for SARS-CoV-2 antibody determination and their comparison and correlation with the virus neutralization test. Diagnostics (Basel). 2021;11(4):593.

Valdivia A, Torres I, Latorre V, et al. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Eur J Clin Microbiol Infect Dis. 2021;40(3):485-494.

Szabó Z, Szabó T, Bodó K, et al. Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors. Pract Lab Med. 2021;25:e00222.

Mitchell J, Connolly CM, Chiang TP, et al. Comparison of SARS-CoV-2 antibody response after 2-dose mRNA-1273 vs BNT162b2 vaccines in incrementally immunosuppressed patients. JAMA Netw Open. 2022;5(5):e2211897.

Haller MC, Kaiser RA, Langthaler S, et al. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA vaccine immunogenicity in kidney transplant recipients. Transpl Int. 2022;35:10026.

Fernández-Ruiz M, Almendro-Vázquez P, Carretero O, et al. Discordance between SARS-CoV-2-specific cell-mediated and antibody responses elicited by mRNA-1273 vaccine in kidney and liver transplant recipients. Transplant Direct. 2021;7(12):e794.

Schmidt T, Klemis V, Schub D, et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am J Transplant. 2021;21(12):3990-4002.

Mulley WR, Dendle C, Ling JEH, et al. Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Heart Lung Transplant. 2018;37(7):844-852.

Abu-Khader A, Wang W, Berka M, Galaszkiewicz I, Khan F, Berka N. SARS Cov-2 vaccination induces de novo donor-specific HLA antibodies in a renal transplant patient on waiting list: a case report. HLA. 2022;99(1):25-30.

Cassaniti I, Gregorini M, Bergami F, et al. Effect of a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine on humoral and cellular responses and serum anti-HLA antibodies in kidney transplant recipients. Vaccines (Basel). 2022;10(6):921.

Wijtvliet VPWM, Verheyden S, Depreter B, et al. SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies. Transpl Immunol. 2022;74:101670.

Russo G, Lai Q, Poli L, et al. SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: risk factors for impaired response and immunological implications. Clin. Transplant. 2022;36(1):e14495.

Kumar D, Hu Q, Samson R, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am J Transplant. 2022;22(8):2089-2093.

Karaba AH, Johnston TS, Aytenfisu TY, et al. A fourth dose of COVID-19 vaccine does not induce neutralization of the Omicron variant among solid organ transplant recipients with suboptimal vaccine response. Transplantation. 2022;106(7):1440-1444.

Benning L, Morath C, Bartenschlager M, et al. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am J Transplant. 2022;22(7):1873-1883.

Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188-2200.

Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022;28:1297-1302.

Chalkias S, Harper C, Vrbicky K, et al. A bivalent Omicron-containing booster vaccine against Covid-19. N Engl J Med. 2022;387(14):1279-1291.

Anft M, Skrzypczyk S, Frahnert M, et al. Immunogenicity of bivalent Omicron BA.4/5 adapted vaccine in hemodialysis patients. Kidney Int Rep. 2023;8(4):939-941.